Diabetic Retinopathy/Diabetic Macular Edema TreatmentTrends | EU | 2015

TreatmentTrends: Diabetic Retinopathy/Diabetic Macular Edema (EU) is the inaugural report in an annual syndicated report series that offers a snapshot of the diabetic retinopathy (DR) and diabetic macular edema (DME) market dynamics and competitive landscape through comprehensive primary research with retinal specialists and general ophthalmologists in each of the EU5 countries (France, Germany, Italy, Spain, United Kingdom). The report provides valuable insight into the current and anticipated treatment of patients with DR (including nonproliferative DR [NPDR] and proliferative DR [PDR]) and DME (including focal and diffuse), with a particular focus on the use of intravitreal pharmacotherapy, specifically anti-vascular endothelial growth factor (VEGF) agents and long-acting corticosteroid implants. We also assess surveyed physicians’ perceptions of these products for DME—e.g., their advantages and disadvantages, ideal patient types, barriers to growth—and current detailing and messaging efforts for approved DME brands. Finally, respondents are queried about their awareness of and interest in products in development DME.

Login to access report